In this study, we used RT-PCR and IHC to analyze RRM1 and ERCC1 mRNA and protein expression in PDA specimens. PDA patients with low expression of RRM1 by IHC derived benefit from gemcitabine-based chemotherapy. Assessment of RRM1 mRNA expression was limited by the small sample size. Low ERCC1 expression by RT-PCR was associated with a 2.5 times higher risk of mortality than high expression (p=0.031). There was no association between ERCC1 expression by IHC and survival; however, agreement between mRNA and protein expression was poor for ERCC1. This study demonstrates the ERCC1 and RRM1 expression have an impact on the survival of PDA patients treated with gemcitabine.
Recommended CitationHoldbrook, Thomas; Danenberg, Kathleen D.; Satti, Suneeta; Kline, Jessica; Yeo, Charles J.; Brody, Jonathan R.; McCue, Peter; and Witkiewicz, Agnieszka K., "ERCC1 and RRM1 as Predictors of Survival and Response in Pancreatic Ductal Adenocarcinoma Treated with Gemcitabine-Based Chemotherapy" (2011). Department of Surgery Faculty Papers. Paper 36.